Oragenics Inc. Secures $16.5 Million to Advance Intranasal Concussion Therapy

July 3rd, 2025 1:05 PM
By: Newsworthy Staff

Oragenics Inc. has raised $16.5 million through a preferred stock offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in treating neurological disorders.

Oragenics Inc. Secures $16.5 Million to Advance Intranasal Concussion Therapy

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company, has successfully closed a public offering of Series H Convertible Preferred Stock and Warrants, raising approximately $16.5 million. This financial boost is earmarked for the clinical development of ONP-002, a novel intranasal therapy aimed at treating concussions, alongside repaying a $3 million bridge note and supporting ongoing research and development efforts. The offering involved the sale of 660,000 units at $25.00 each, with each unit comprising one share of Series H Convertible Preferred Stock and one Warrant, potentially bringing in an additional $16.5 million if all Warrants are exercised. Dawson James Securities served as the sole placement agent for this offering. This development underscores the company's commitment to advancing innovative treatments for neurological disorders, with ONP-002 representing a promising avenue for addressing the unmet medical needs of individuals suffering from concussions.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
;